The information on this web site is intended for use only by healthcare professionals in the United States.

Discover LYMPHOSEEK, the only agent designed, studied, proven, and FDA-approved for lymphatic mapping in patients with solid tumors; guiding Sentinel lymph node biopsy in patients with breast cancer, melanoma, and squamous cell carcinoma of the oral cavity; and use with lymphoscintigraphy.

Click to watch LYMPHOSEEK in action


In October 2014, the FDA approved the expanded use of LYMPHOSEEK as a lymphatic mapping agent for solid tumors where it is a component of the intraoperative procedure.
Learn More

Designed to Identify

LYMPHOSEEK allows for timely and precise identification of tumor-draining lymph nodes.2,3
Learn More


LYMPHOSEEK is a radioactive diagnostic agent indicated with or without scintigraphic imaging for:

  • Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management.
  • Guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.

Important Safety Information

In clinical trials with LYMPHOSEEK, no serious hypersensitivity reactions were reported, however LYMPHOSEEK may pose a risk of such reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs).

Prior to the administration of LYMPHOSEEK, patients should be asked about previous hypersensitivity reactions to drugs, in particular dextran and modified forms of dextran. Resuscitation equipment and trained personnel should be available at the time of LYMPHOSEEK administration, and patients observed for signs or symptoms of hypersensitivity following injection.

Any radiation-emitting product may increase the risk for cancer. Adhere to dose recommendations and ensure safe handling to minimize the risk for excessive radiation exposure to patients or health care workers.

In clinical trials, no patients experienced serious adverse reactions and the most common adverse reactions were injection site irritation and/or pain (<1%).

Please see full Prescribing Information.

To report suspected adverse reactions, contact Cardinal Health at 1-800-476-5270 or FDA at 1 800-FDA-1088 or